3/26
08:19 am
mura
Mural Oncology plc (NASDAQ: MURA) had its price target lowered by analysts at HC Wainwright from $18.00 to $6.00. They now have a "buy" rating on the stock.
Medium
Report
Mural Oncology plc (NASDAQ: MURA) had its price target lowered by analysts at HC Wainwright from $18.00 to $6.00. They now have a "buy" rating on the stock.
3/25
01:06 pm
mura
Mural Oncology plc (NASDAQ: MURA) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.
Medium
Report
Mural Oncology plc (NASDAQ: MURA) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.
3/25
12:18 pm
mura
Mural Oncology plc (NASDAQ: MURA) was downgraded by analysts at Raymond James from a "strong-buy" rating to an "outperform" rating. They now have a $18.00 price target on the stock.
Low
Report
Mural Oncology plc (NASDAQ: MURA) was downgraded by analysts at Raymond James from a "strong-buy" rating to an "outperform" rating. They now have a $18.00 price target on the stock.
3/25
08:40 am
mura
Mural Oncology plc (NASDAQ: MURA) had its "hold" rating re-affirmed by analysts at Jones Trading.
High
Report
Mural Oncology plc (NASDAQ: MURA) had its "hold" rating re-affirmed by analysts at Jones Trading.
3/25
06:30 am
mura
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
High
Report
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
3/12
08:05 am
mura
Mural Oncology plc (NASDAQ: MURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Low
Report
Mural Oncology plc (NASDAQ: MURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
3/11
04:01 pm
mura
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
Low
Report
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
2/18
07:00 am
mura
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Medium
Report
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
1/9
04:00 pm
mura
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
Low
Report
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts